Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherClinical Investigations (Human)

Prevalence and outcomes of cardiac amyloidosis in all-comer referrals for bone scintigraphy

Christian Nitsche, Katharina Mascherbauer, Raffaella Calabretta, Matthias Koschutnik, Carolina Dona, Varius Dannenberg, Felix Hofer, Kseniya Halavina, Andreas Kammerlander, Tatjana Traub-Weidinger, Georg Goliasch, Christian Hengstenberg, Marcus Hacker and Julia Mascherbauer
Journal of Nuclear Medicine June 2022, jnumed.122.264041; DOI: https://doi.org/10.2967/jnumed.122.264041
Christian Nitsche
Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christian Nitsche
Katharina Mascherbauer
Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raffaella Calabretta
Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Koschutnik
Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolina Dona
Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Varius Dannenberg
Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Felix Hofer
Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kseniya Halavina
Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Kammerlander
Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andreas Kammerlander
Tatjana Traub-Weidinger
Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georg Goliasch
Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Hengstenberg
Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcus Hacker
Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Mascherbauer
Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

AIMS: The prevalence of cardiac amyloidosis (CA) in the general population and associated prognostic implications remain poorly understood. We aimed to identify CA prevalence and outcomes in bone scintigraphy referrals. METHODS AND RESULTS: Consecutive all-comers undergoing 99mtechnetium-3,3-diphosphono-1,2-propanodicarboxylic-acid (DPD) bone scintigraphy between 2010 and 2020 were included. Perugini grade-1 was defined as low-grade uptake and grade-2/3 as confirmed CA. All-cause mortality, cardiovascular death and heart failure hospitalization (HHF) served as endpoints. In total, 17,387 scans from 11,527 subjects (61±16 y/o, 63.0% female, 73.6% cancer) were analyzed. Prevalence of DPD positivity was 3.3% (n = 376/11,527; grade-1: 1.8%, grade-2/3: 1.5%), and was higher among cardiac vs. non-cardiac referrals (18.2% vs. 1.7%). In individuals with >1 scan, progression from grade-1 to grade-2/3 was observed. Among patients with biopsy-proven CA, the portion of light-chain (AL)-CA was significantly higher in grade-1 vs. grade-2/3 (73.3% vs. 15.4%). After a median of 6 years, clinical event rates were: 29.4% mortality, 2.6% cardiovascular death, and 1.5% HHF, all independently predicted by positive DPD. Overall, adverse outcomes were driven by confirmed CA (vs. grade-0, mortality: adjusted hazard ratio [AHR] 1.46 [95% confidence interval 1.12-1.90]; cardiovascular death: AHR 2.34 [1.49-3.68]; HHF: AHR 2.25 [1.51-3.37]). One-year mortality was substantially higher in cancer vs. non-cancer patients. Among non-cancer patients, also grade-1 had worse outcomes than grade-0 (HHF/death: AHR 1.45 [1.01-2.09]), presumably due to longer observation/higher prognostic impact of early infiltration. CONCLUSION: Positive DPD was identified in a substantial number of consecutive DPD referrals and associated with adverse outcomes.

  • Bone
  • Cardiology (basic/technical)
  • Cardiology (clinical)
  • ATTR
  • diagnosis
  • heart failure
  • mortality
  • transthyretin
  • Copyright © 2022 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 63 (6)
Journal of Nuclear Medicine
Vol. 63, Issue 6
June 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prevalence and outcomes of cardiac amyloidosis in all-comer referrals for bone scintigraphy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Prevalence and outcomes of cardiac amyloidosis in all-comer referrals for bone scintigraphy
Christian Nitsche, Katharina Mascherbauer, Raffaella Calabretta, Matthias Koschutnik, Carolina Dona, Varius Dannenberg, Felix Hofer, Kseniya Halavina, Andreas Kammerlander, Tatjana Traub-Weidinger, Georg Goliasch, Christian Hengstenberg, Marcus Hacker, Julia Mascherbauer
Journal of Nuclear Medicine Jun 2022, jnumed.122.264041; DOI: 10.2967/jnumed.122.264041

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Prevalence and outcomes of cardiac amyloidosis in all-comer referrals for bone scintigraphy
Christian Nitsche, Katharina Mascherbauer, Raffaella Calabretta, Matthias Koschutnik, Carolina Dona, Varius Dannenberg, Felix Hofer, Kseniya Halavina, Andreas Kammerlander, Tatjana Traub-Weidinger, Georg Goliasch, Christian Hengstenberg, Marcus Hacker, Julia Mascherbauer
Journal of Nuclear Medicine Jun 2022, jnumed.122.264041; DOI: 10.2967/jnumed.122.264041
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma
  • Intraoperative molecular fluorescence imaging of pancreatic cancer by targeting vascular endothelial growth factor: A multicenter feasibility dose-escalation study
Show more Clinical Investigations (Human)

Clinical (Cardiovascular)

  • Explainable Deep Learning Improves Physician Interpretation of Myocardial Perfusion Imaging
  • Sex Differences and Caffeine Impact in Adenosine-Induced Hyperemia
Show more Clinical (Cardiovascular)

Similar Articles

Keywords

  • Bone
  • Cardiology (basic/technical)
  • Cardiology (clinical)
  • ATTR
  • diagnosis
  • heart failure
  • mortality
  • transthyretin
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire